Key result
Defective interfering particles (DIPs) are truncated viral genomes that interfere with standard virus replication, establish persistent infections, and show potential as novel antiviral therapeutics.
Why the study?
Although DIP-mediated virus interference and host cell persistence have been reported, the processes involved in modifying or influencing the fate of a viral infection remain poorly understood.
This review highlights the biological mechanisms of defective interfering particles and their potential application as antiviral therapies.
DIPs should not yet alter antiviral practice; leaves open their development as targeted therapeutics.
Defective interfering particles (DIPs) were first described by Preben von Magnus as a non-infectious form of influenza virus arising due to undiluted passages of the virus in embryonated eggs. DIPs are characterized by internal deletions in the viral genome, interference with the standard virus replication, attenuation of cytopathic effects and viral persistence. Even though DIP-mediated virus interference and host cell persistence have been reported with both experimental and natural infections, the processes involved in modifying or influencing the fate of a viral infection are poorly understood. In this review, the properties of DIPs, the mechanisms involved in interference and viral persistence in modulation of disease outcomes and their possibilities towards an antiviral approach have been highlighted.
No takes yet. Share an insight, caveat, or question.
Bora et al. (2025) conducted a review in Viral infections. Defective interfering particles (DIPs) was evaluated. Defective interfering particles (DIPs) are truncated viral genomes that interfere with standard virus replication, establish persistent infections, and show potential as novel antiviral therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: